Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Anti-Metastatic Effects on Melanoma via Intravenous Administration of Anti-NF-κB siRNA Complexed with Functional Peptide-Modified Nano-Micelles.

Ibaraki H, Kanazawa T, Owada M, Iwaya K, Takashima Y, Seta Y.

Pharmaceutics. 2020 Jan 15;12(1). pii: E64. doi: 10.3390/pharmaceutics12010064.

2.
3.

Therapeutic Effects in a Transient Middle Cerebral Artery Occlusion Rat Model by Nose-To-Brain Delivery of Anti-TNF-Alpha siRNA with Cell-Penetrating Peptide-Modified Polymer Micelles.

Kanazawa T, Kurano T, Ibaraki H, Takashima Y, Suzuki T, Seta Y.

Pharmaceutics. 2019 Sep 15;11(9). pii: E478. doi: 10.3390/pharmaceutics11090478. Erratum in: Pharmaceutics. 2019 Dec 17;11(12):.

4.

Anti-RelA siRNA-Encapsulated Flexible Liposome with Tight Junction-Opening Peptide as a Non-invasive Topical Therapeutic for Atopic Dermatitis.

Ibaraki H, Kanazawa T, Kurano T, Oogi C, Takashima Y, Seta Y.

Biol Pharm Bull. 2019;42(7):1216-1225. doi: 10.1248/bpb.b19-00259.

5.

Transdermal anti-nuclear kappaB siRNA therapy for atopic dermatitis using a combination of two kinds of functional oligopeptide.

Ibaraki H, Kanazawa T, Takashima Y, Okada H, Seta Y.

Int J Pharm. 2018 May 5;542(1-2):213-220. doi: 10.1016/j.ijpharm.2018.03.026. Epub 2018 Mar 15.

PMID:
29551748
6.

Intra-articular Retention and Anti-arthritic Effects in Collagen-Induced Arthritis Model Mice by Injectable Small Interfering RNA Containing Hydrogel.

Kanazawa T, Tamano K, Sogabe K, Endo T, Ibaraki H, Takashima Y, Seta Y.

Biol Pharm Bull. 2017;40(11):1929-1933. doi: 10.1248/bpb.b17-00481.

7.

Enhancement of nose-to-brain delivery of hydrophilic macromolecules with stearate- or polyethylene glycol-modified arginine-rich peptide.

Kanazawa T, Kaneko M, Niide T, Akiyama F, Kakizaki S, Ibaraki H, Shiraishi S, Takashima Y, Suzuki T, Seta Y.

Int J Pharm. 2017 Sep 15;530(1-2):195-200. doi: 10.1016/j.ijpharm.2017.07.077. Epub 2017 Jul 27.

PMID:
28757255
8.

Systemic delivery of small interfering RNA targeting nuclear factor κB in mice with collagen-induced arthritis using arginine-histidine-cysteine based oligopeptide-modified polymer nanomicelles.

Kanazawa T, Endo T, Arima N, Ibaraki H, Takashima Y, Seta Y.

Int J Pharm. 2016 Dec 30;515(1-2):315-323. doi: 10.1016/j.ijpharm.2016.10.033. Epub 2016 Oct 17.

PMID:
27765724
9.

Development of an Innovative Intradermal siRNA Delivery System Using a Combination of a Functional Stearylated Cytoplasm-Responsive Peptide and a Tight Junction-Opening Peptide.

Ibaraki H, Kanazawa T, Takashima Y, Okada H, Seta Y.

Molecules. 2016 Sep 24;21(10). pii: E1279. doi: 10.3390/molecules21101279.

10.

Versatile nuclear localization signal-based oligopeptide as a gene vector.

Kanazawa T, Yamazaki M, Fukuda T, Takashima Y, Okada H.

Biol Pharm Bull. 2015;38(4):559-65. doi: 10.1248/bpb.b14-00706.

11.

Prolongation of life in rats with malignant glioma by intranasal siRNA/drug codelivery to the brain with cell-penetrating peptide-modified micelles.

Kanazawa T, Morisaki K, Suzuki S, Takashima Y.

Mol Pharm. 2014 May 5;11(5):1471-8. doi: 10.1021/mp400644e. Epub 2014 Apr 16.

PMID:
24708261
12.

Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery.

Tanaka K, Kanazawa T, Horiuchi S, Ando T, Sugawara K, Takashima Y, Seta Y, Okada H.

Int J Pharm. 2013 Oct 15;455(1-2):40-7. doi: 10.1016/j.ijpharm.2013.07.069. Epub 2013 Aug 1.

PMID:
23911914
13.

Needle-free intravaginal DNA vaccination using a stearoyl oligopeptide carrier promotes local gene expression and immune responses.

Kanazawa T, Tamura T, Yamazaki M, Takashima Y, Okada H.

Int J Pharm. 2013 Apr 15;447(1-2):70-4. doi: 10.1016/j.ijpharm.2013.02.018. Epub 2013 Feb 27.

PMID:
23454850
14.

[Non-invasive ophthalmic liposomes for nucleic acid delivery to posterior segment of eye].

Takashima Y, Tsuchiya T, Igarashi Y, Kanazawa T, Okada H, Urtti A.

Yakugaku Zasshi. 2012;132(12):1365-70. Review. Japanese.

15.

Improved intestinal absorption of a poorly water-soluble oral drug using mannitol microparticles containing a nanosolid drug dispersion.

Nishino Y, Kubota A, Kanazawa T, Takashima Y, Ozeki T, Okada H.

J Pharm Sci. 2012 Nov;101(11):4191-200. doi: 10.1002/jps.23278. Epub 2012 Aug 2.

PMID:
22864998
16.

Vaginal DNA vaccination against infectious diseases transmitted through the vagina.

Kanazawa T, Takashima Y, Okada H.

Front Biosci (Elite Ed). 2012 Jun 1;4:2340-53. Review.

PMID:
22652641
17.

Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-modified MPEG-PCL nanomicelles.

Kanazawa T, Sugawara K, Tanaka K, Horiuchi S, Takashima Y, Okada H.

Eur J Pharm Biopharm. 2012 Aug;81(3):470-7. doi: 10.1016/j.ejpb.2012.04.021. Epub 2012 May 2.

PMID:
22579732
18.

Intranasal delivery of camptothecin-loaded tat-modified nanomicells for treatment of intracranial brain tumors.

Taki H, Kanazawa T, Akiyama F, Takashima Y, Okada H.

Pharmaceuticals (Basel). 2012 Oct 15;5(10):1092-102. doi: 10.3390/ph5101092.

19.

A cytoplasm-sensitive peptide vector cross-linked with dynein light chain association sequence (DLCAS) enhances gene expression.

Tanaka K, Kanazawa T, Sugawara K, Horiuchi S, Takashima Y, Okada H.

Int J Pharm. 2011 Oct 31;419(1-2):231-4. doi: 10.1016/j.ijpharm.2011.07.007. Epub 2011 Jul 12.

PMID:
21782009
20.

The characterization of protein release from sericin film in the presence of an enzyme: towards fibroblast growth factor-2 delivery.

Nishida A, Naganuma T, Kanazawa T, Takashima Y, Yamada M, Okada H.

Int J Pharm. 2011 Jul 29;414(1-2):193-202. doi: 10.1016/j.ijpharm.2011.05.033. Epub 2011 May 17.

PMID:
21619916

Supplemental Content

Loading ...
Support Center